Advertisement
- United States
- /
- Semiconductors
- /
- NasdaqGS:FORM
Why FormFactor (FORM) Is Up 7.1% After Margin-Focused Q4 Results And 2026 Guidance Update
Reviewed by Sasha Jovanovic
- In early February 2026, FormFactor, Inc. reported fourth-quarter 2025 sales of US$215.16 million and net income of US$23.22 million, alongside guidance for first-quarter 2026 revenue of about US$225 million and net income per diluted share of roughly US$0.11.
- Management pointed to efficiency gains, such as workforce reductions, better manufacturing yields, and shorter production cycle times, as key drivers of improved gross margins and investor optimism around its advanced semiconductor testing business.
- We’ll now assess how these margin-focused operational improvements shape FormFactor’s existing investment narrative and its prospects in advanced semiconductor testing.
Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
FormFactor Investment Narrative Recap
To own FormFactor, you need to believe its focus on advanced semiconductor testing and margin improvement can offset cyclical swings in DRAM and HBM demand. The latest quarter supports the view that operational efficiency is a key near term catalyst, while demand volatility across a concentrated customer base remains the biggest risk. The new guidance does not fundamentally change that risk, but it does put more attention on whether recent gross margin gains prove sustainable.
The most relevant recent development here is FormFactor’s Q1 2026 outlook for about US$225 million in revenue and US$0.11 in diluted EPS. Set against Q4 2025’s improved profitability, this softer earnings guide highlights how mix shifts, ramp costs at the Farmers Branch facility, and broader DRAM and HBM demand swings can still weigh on near term margins, even as the company talks up efficiency gains and share opportunities in advanced test.
But before getting too comfortable with the margin story, investors should be aware of how concentrated HBM ramps and new Texas capacity could still...
Read the full narrative on FormFactor (it's free!)
FormFactor’s narrative projects $984.3 million in revenue and $97.0 million in earnings by 2028.
Uncover how FormFactor's forecasts yield a $67.88 fair value, a 30% downside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were much more cautious, assuming revenue of about US$925.3 million and earnings of roughly US$91.3 million by 2028, so if you are excited by Q4’s margin progress and HBM exposure, it is worth remembering that these more pessimistic views highlight how rising costs and capital needs could still limit the payoff from today’s efficiency gains.
Explore 6 other fair value estimates on FormFactor - why the stock might be worth as much as $88.00!
Build Your Own FormFactor Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your FormFactor research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
- Our free FormFactor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FormFactor's overall financial health at a glance.
No Opportunity In FormFactor?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Outshine the giants: these 28 early-stage AI stocks could fund your retirement.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Find 53 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:FORM
FormFactor
Designs, manufactures, and sells probe cards, analytical probes, probe stations, thermal systems, cryogenic systems, and related services in the United States, South Korea, Taiwan, China, Japan, Singapore, Europe, Malaysia, and internationally.
Flawless balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Advertisement
Weekly Picks
LO
Lou_Basenese on Optimi Health ·
The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist
Fair Value:US$1157.5% undervalued
47 followersusers have followed this narrative
2 commentsusers have commented on this narrative
7 likesusers have liked this narrative
WE
WealthAP on Novo Nordisk ·
Novo Nordisk (NVO): Is the "Easy Growth" Story Over?
Fair Value:DKK 407.7721.4% undervalued
68 followersusers have followed this narrative
0 commentsusers have commented on this narrative
8 likesusers have liked this narrative
VA
ValueInvestingSubstack on Zoetis ·
Zoetis down -50% over the past year
Fair Value:US$92.9218.9% undervalued
23 followersusers have followed this narrative
0 commentsusers have commented on this narrative
9 likesusers have liked this narrative
CE
CentryResearch on Centrus Energy ·
Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.
Fair Value:US$19013.7% undervalued
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
10 likesusers have liked this narrative
Recently Updated Narratives
WI
WisetoWealth on PayPal Holdings ·
The Underrated Transformation of a Digital Payments Giant
Fair Value:US$90.3137.8% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
BL
Blagget on Terra Balcanica Resources ·
The C$4M Explorer Positioned to Become Europe's First Antimony Mine
Fair Value:CA$0.487.5% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
DA
david_6nroa on Charter Communications ·
Charter is undervalued - Here's why.
Fair Value:US$87.0741.6% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
CU
CubanEros on Microsoft ·
A wonderful business at reasonable price.
Fair Value:US$419.919.1% undervalued
81 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
OS
oscargarcia on NVIDIA ·
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
Fair Value:US$28026.1% undervalued
185 followersusers have followed this narrative
9 commentsusers have commented on this narrative
15 likesusers have liked this narrative
BE
benjamin_lvieq on PayPal Holdings ·
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6513.6% undervalued
71 followersusers have followed this narrative
2 commentsusers have commented on this narrative
11 likesusers have liked this narrative
Trending Discussion
DE
derek_3wsdg on Teladoc Health ·
You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.
1
|0
